Oryzon Nominates Specific LSD1 Inhibitor as Drug Candidate to Enter…

Oryzon announced today that it is entering preclinical development with its second drug candidate, a first-in-class specific Lysine Specific Demethylase 1 (LSD1) inhibitor for the treatment of...

(PRWeb May 24, 2012)

Read the full story at http://www.prweb.com/releases/2012/5/prweb9533996.htm


Comments are closed.